Clinical trials: Advanced Solid Tumors (Phase 1)
Solid Tumor
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of novel autologous hypoxia-activated CAR-T cell therapy targeting CD73 and AXL ( CD73/AXL.HypoSti.CAR-T) will be evaluated in…
- Trial name
- NCT06939270
- Testing
- CD73/AXL.HypoSti.CAR-T cells, Albumin-Bound Paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer, Gastric Cancer
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05678205
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States, South Korea
- Sponsor
- Artiva Biotherapeutics, Inc.
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Advanced Solid Tumor
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors.
- Trial name
- NCT07839819
- Testing
- PM54, Irinotecan, Doxorubicin
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 231 people
- Sponsor
- PharmaMar
Advanced Malignant Solid Tumors
Study Evaluating Safety And Tolerability, Solid Tumor
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
- Trial name
- NCT00768469
- Testing
- Neratinib, Paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Puma Biotechnology, Inc.
Tumor, Solid
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT03486301)
- Testing
- BDB001 (EIK1001), Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- Eikon Therapeutics
Advanced Solid Tumor, Non Small Cell Lung Cancer
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A*03:01-positive adult patients with advanced solid tumors that harbor…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
- Trial name
- NCT07650357
- Testing
- CLSP-5282
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Clasp Therapeutics, Inc.
Solid Metastatic Tumor
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
A Phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. Patients with metastatic or unresectable locally advanced malignant solid tumors will be enrolled and treated…
- Trial name
- NCT04134312
- Testing
- MVA-BN-Brachyury
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Bavarian Nordic
Advanced Solid Tumor (Phase 1)
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.
- Trial name
- NCT06527300
- Testing
- NHWD-870 HCl
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Advanced Solid Tumor, Liver Metastases
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic…
- Trial name
- NCT00501605
- Testing
- AZD2171
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Neoplasms
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.
- Trial name
- NCT02171702
- Testing
- BIBW 2992
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, NSCLC
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab.
- Conditions
- Ovarian Cancer, NSCLC, ESCC, Solid Tumors
- Trial name
- NCT04939701
- Testing
- ASP0739
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumours
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
This is a 3-part study in patients with advanced solid tumours: Part A will assess the effect of itraconazole on the PK parameters of olaparib and will determine the effect of olaparib on the QT interval following single oral…
- Trial name
- NCT01900028
- Testing
- Pharmacokinetic sampling, Olaparib tablet dosing, Itraconazole
- Where
- 14 sites in Belgium, Denmark and 2 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
- Trial name
- NCT05954312
- Testing
- VVD-130037, Docetaxel, Paclitaxel
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 290 people
- Sponsor
- Vividion Therapeutics, Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Ovarian Cancer, Peritoneal Cavity Cancer
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00825201
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Solid Tumor, Adult
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects…
- Trial name
- Zotatifin (NCT04092673)
- Testing
- eFT226, Sotorasib, Fulvestrant
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- Effector Therapeutics
Advanced Solid Tumor, B Cell Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma.
- Trial name
- NCT04418141
- Testing
- CN1
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.